Linklaters' Schmidt on Pfizer-Wyeth review

The approval by U.S. antitrust regulators of Pfizer Inc.'s (NYSE:PFE) acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration. That's according to Jeffrey Schmidt, a partner with Linklaters and a former director of the Federal Trade Commission's office of competition under President George W. Bush. Schmidt, who will be discussing the antitrust...